Dr. Lori S. Muffly, M.D.
Hematology (Hematology (Internal Medicine) Physician)
300 Pasteur Dr
Stanford, CA 94305
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 77
Licensed in Colorado since 2013, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: Jefferson Medical College of Thomas Jefferson University
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
CA license A132153 (first issued 2014; current) -
Hematology & Oncology Physician
CA license A132153 (first issued 2014; current) · CO license DR.0052339 (first issued 2013; expired) -
Internal Medicine Physician
NH license RT1744 -
Medical Oncology Physician
CA license A132153 (first issued 2014; current) · CO license 52339 (first issued 2013; expired)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Stanford Health Care Stanford, CA
Medical groups
- Stanford Health Care (3,122 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 77
- Services billed
- 381
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 190 | 56 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 177 | 24 |
| Hospital discharge day management, more than 30 minutes | 12 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 111 |
| Acyclovir Other prescribers in Stanford, CA | 106 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Stanford, CA | 37 |
| Rezurock (belumosudil mesylate) | 24 |
| Prednisone Other prescribers in Stanford, CA | 20 |
| Posaconazole | 16 |
| Tacrolimus Other prescribers in Stanford, CA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 22 payments worth $23,050 in total to this clinician.
| Incyte Corporation | $7,739 |
|---|---|
| Autolus Inc | $5,775 |
| Gilead Sciences, Inc. | $5,452 |
| National Marrow Donor Program | $3,338 |
| Astellas Pharma Global Development | $620 |
| Merck Sharp & Dohme LLC | $81.38 |
| Janssen Biotech, Inc. | $44.02 |
| Consulting Fee | $12,922 |
|---|---|
| Honoraria | $5,558 |
| Travel and Lodging | $3,067 |
| Food and Beverage | $1,428 |
| Gift | $75.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Autolus Inc Dec 5, 2025 | Honoraria in-kind | $5,558 |
| Gilead Sciences, Inc. Jul 10, 2025 | Consulting FeeCompany’s description;4100489;GTF;11846037 | $4,002 |
| Incyte Corporation Dec 18, 2025 | Consulting Fee Niktimvo · Oncology | $3,425 |
| Incyte Corporation Jul 31, 2025 | Consulting Fee Niktimvo · Oncology | $3,425 |
| Gilead Sciences, Inc. Jan 13, 2025 | Consulting FeeCompany’s description;3894869;GTF;11846037 | $1,450 |
| National Marrow Donor Program Sep 24, 2025 | Travel and Lodging travel to MINNEAPOLIS, MN · in-kind | $1,041 |
| Incyte Corporation Apr 24, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Denver, CO | $741 |
| National Marrow Donor Program Jan 30, 2025 | Travel and Lodging travel to Austin, TX · in-kind | $680 |
| Astellas Pharma Global Development Nov 21, 2025 | Consulting Fee Xospata · Oncology | $620 |
| National Marrow Donor Program Sep 25, 2025 | Travel and Lodging travel to MINNEAPOLIS, MN · in-kind | $447 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Dec 18, 2025 | Consulting Fee Niktimvo · Oncology | $3,425 |
| Autolus Inc Dec 5, 2025 | Honoraria in-kind | $5,558 |
| National Marrow Donor Program Dec 1, 2025 | Gift in-kind | $75.00 |
| Astellas Pharma Global Development Nov 21, 2025 | Consulting Fee Xospata · Oncology | $620 |
| National Marrow Donor Program Oct 31, 2025 | Travel and Lodging travel to MINNEAPOLIS, MN · in-kind | $158 |
| National Marrow Donor Program Sep 25, 2025 | Travel and Lodging travel to MINNEAPOLIS, MN · in-kind | $447 |
| National Marrow Donor Program Sep 24, 2025 | Travel and Lodging travel to MINNEAPOLIS, MN · in-kind | $1,041 |
| Incyte Corporation Jul 31, 2025 | Consulting Fee Niktimvo · Oncology | $3,425 |
| Gilead Sciences, Inc. Jul 10, 2025 | Consulting FeeCompany’s description;4100489;GTF;11846037 | $4,002 |
| Incyte Corporation Apr 24, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Denver, CO | $741 |
| National Marrow Donor Program Jan 30, 2025 | Travel and Lodging travel to Austin, TX · in-kind | $680 |
| Gilead Sciences, Inc. Jan 13, 2025 | Consulting FeeCompany’s description;3894869;GTF;11846037 | $1,450 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $1,089,278 in research payments for these studies, mostly to the institutions running them.
- Understanding Patient Access to CAR-T Therapy, Scoping Phase 1
Kite Pharma, Inc. - Real World Outcomes Collaborative of CAR T-Cell Therapies in Adult Acute Lymphoblastic Leukemia (ROCCA)
Kite Pharma, Inc. - ISR: Phase 1b Study of Brexucabtagene Autoleucel plus Dasatinib in Adults with Acute Lymphoblastic Leukemia
Kite Pharma, Inc. - ACCESS-T: Phase 1 Trial for Patients with Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation from an HLA-Mismatched Donor (7/8) with Orca-T
Incyte Corporation - Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events (MEASURE)
National Marrow Donor Program - Facilitating Activation of Study Trials (FAST)
National Marrow Donor Program
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.